Wide Ranks

ADMA

ADMA Biologics Inc

21.83

Top Statistics
Market Cap 5 B Forward PE 30.01 Revenue Growth 78.10 %
Current Ratio 7.09 Trailing PE 80.85 Earnings Growth 1400.00 %
Profit Margins 17.80 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 41.19 Enterprise / Revenue 13.54 Price To Sales Trailing12 Months 13.48
Profitability
Profit Margins 17.80 % Operating Margins 33.08 %
Balance Sheet
Total Cash 86 M Total Cash Per Share 0.3670 Total Debt 111 M
Total Debt To Equity 48.03 Current Ratio 7.09 Book Value Per Share 0.9810
All Measures
Short Ratio 361.00 % Message Board Id finmb_51119246 Fax 201 478 5553
Shares Short Prior Month 16 M Return On Equity 0.3555 City Ramsey
Uuid 98c34fdf-5e27-3b32-9f32-8b49c01ae8aa Previous Close 21.82 First Trade Date Epoch Utc 1 B
Book Value 0.9810 Beta 0.6450 Total Debt 111 M
Volume 1 M Price To Book 22.25 Fifty Two Week Low 3.60
Total Cash Per Share 0.3670 Total Revenue 382 M Shares Short Previous Month Date 1 B
Target Median Price 25.00 Audit Risk 8 Max Age 86400
Recommendation Mean 1.20 Sand P52 Week Change 0.3133 Operating Margins 33.08 %
Target Mean Price 23.45 Net Income To Common 68 M Short Percent Of Float 0.0620
Implied Shares Outstanding 236 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 2 M Average Volume10days 2 M Total Cash 86 M
Next Fiscal Year End 1 B Revenue Per Share 1.66 Held Percent Insiders 0.0251
Ebitda Margins 32.89 % Trailing PE 80.85 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 21.82
Target Low Price 17.23 Gmt Off Set Milliseconds -18000000 Fifty Day Average 19.03
Open 21.84 Free Cashflow 45 M State NJ
Dividend Yield 0.00 % Return On Assets 0.1989 Time Zone Short Name EST
Board Risk 6 Trailing Eps 0.2700 Day Low 21.53
Address1 465 State Route 17 Shares Outstanding 236 M Compensation Risk 7
Price Hint 2 Target High Price 26.00 Website https://www.admabiologics.com
52 Week Change 4.90 Average Volume 5 M Earnings Quarterly Growth 1300.00 %
Forward Eps 0.7200 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 304.80 % Is_sp_500 False Regular Market Day High 22.19
Profit Margins 17.80 % Debt To Equity 48.03 Fifty Two Week High 23.64
Day High 22.19 Shares Short 14 M Regular Market Open 21.84
Industry Key biotechnology Earnings Growth 1400.00 % Enterprise To Revenue 13.54
Revenue Growth 78.10 % Shares Percent Shares Out 0.0602 Operating Cashflow 86 M
Currency USD Time Zone Full Name America/New_York Market Cap 5 B
Is_nasdaq_100 False Zip 07446 Quote Type EQUITY
Industry Biotechnology Long Name ADMA Biologics, Inc. Overall Risk 7
Regular Market Day Low 21.53 Held Percent Institutions 0.9092 Current Price 21.83
Enterprise To Ebitda 41.19 Financial Currency USD Current Ratio 7.09
Gross Margins 49.48 % Industry Disp Biotechnology Number Of Analyst Opinions 5
Country United States Float Shares 232 M Two Hundred Day Average 12.50
Governance Epoch Date 1 B Enterprise Value 5 B Price To Sales Trailing12 Months 13.48
Forward PE 30.01 Regular Market Volume 1 M Ebitda 125 M
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.

pneumonia infection for an immunoglobulin.

In addition, it operates source plasma collection facilities.

The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.

ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.